Global Search

Search articles, concepts, and chapters

Transl Vis Sci TechnolFebruary 20260 citations

Exploration and Application of Multiluminance Mobility Test in Bietti Crystalline Dystrophy.

Chen Yanni, Wu Nan, Meng Xiaohong, Long Yanling, Ren Jiayun, Wang Yu, Liu Xiao, Liu Yong


AI Summary

This study found the MLMT has limited range in advanced Bietti crystalline dystrophy. Preserved central macular structure, not just visual acuity, drives mobility, suggesting MLMT adaptation and structural endpoints are needed for BCD trials.

Abstract

Purpose

This study evaluated the multiluminance mobility test (MLMT) as a functional vision assessment tool for Bietti crystalline dystrophy (BCD) and explored its relationship with structural and visual function parameters.

Methods

A retrospective study of 34 BCD patients (67 eyes) incorporated 2 additional low light levels (0.1 and 0.5 lux) into the MLMT. Visual function assessments included best-corrected visual acuity, visual field (VF), and microperimetry (MP). Macular structure was evaluated via spectral-domain optical coherence tomography. MLMT performance was correlated with these parameters using Spearman's rank correlation tests.

Results

Despite severe global photoreceptor dysfunction, a notable proportion of participants (38.8%) passed the MLMT at 1 lux or less, with 23.9% reaching the lowest luminance (0.1 lux). MLMT lux scores correlated significantly with best-corrected visual acuity (ρ = -0.5322; P = 0.0012), mean defect of VF (ρ = -0.5919; P = 0.0005), and mean macular sensitivity of MP (MS-MP; ρ = 0.7175; P < 0.0001). Subgroup analysis revealed that subjects with preserved foveal ellipsoid zone had significantly higher MLMT lux scores and better MS-MP (both P < 0.05) than those with ellipsoid zone atrophy. Although visual function parameters were markedly impaired in certain patients, their MLMT performance remained relatively favorable.

Conclusions

The standardized MLMT has a limited range for assessing advanced BCD. Preservation of central macular structure, rather than visual acuity alone, appears to be critical for mobility performance in BCD patients. Disease-specific adaptations of functional end points are needed for BCD clinical trials.

Translational relevance: To assess functional vision for BCD, the MLMT requires adaptation, and clinical trials should incorporate macular structural parameters.


Key Concepts5

A retrospective study of 34 Bietti crystalline dystrophy (BCD) patients (67 eyes) evaluating the multiluminance mobility test (MLMT) found that 38.8% of participants passed the MLMT at 1 lux or less, with 23.9% reaching the lowest luminance (0.1 lux), despite severe global photoreceptor dysfunction.

DiagnosisCohortRetrospective Cohort Studyn=34 BCD patients (67 eyes)Ch7

In a retrospective study of 34 Bietti crystalline dystrophy (BCD) patients (67 eyes), MLMT lux scores correlated significantly with best-corrected visual acuity (ρ = -0.5322; P = 0.0012), mean defect of visual field (VF) (ρ = -0.5919; P = 0.0005), and mean macular sensitivity of microperimetry (MS-MP) (ρ = 0.7175; P < 0.0001).

DiagnosisCohortRetrospective Cohort Studyn=34 BCD patients (67 eyes)Ch6Ch7

Subgroup analysis in a retrospective study of 34 Bietti crystalline dystrophy (BCD) patients (67 eyes) revealed that subjects with preserved foveal ellipsoid zone had significantly higher MLMT lux scores and better mean macular sensitivity of microperimetry (MS-MP) (both P < 0.05) than those with ellipsoid zone atrophy.

PrognosisCohortRetrospective Cohort Studyn=34 BCD patients (67 eyes)Ch5Ch7

A retrospective study of 34 Bietti crystalline dystrophy (BCD) patients (67 eyes) concluded that the standardized multiluminance mobility test (MLMT) has a limited range for assessing advanced BCD.

DiagnosisCohortRetrospective Cohort Studyn=34 BCD patients (67 eyes)Ch7

A retrospective study of 34 Bietti crystalline dystrophy (BCD) patients (67 eyes) found that preservation of central macular structure, rather than visual acuity alone, appears to be critical for mobility performance in BCD patients.

PrognosisCohortRetrospective Cohort Studyn=34 BCD patients (67 eyes)Ch5Ch7

Is this article assigned to the wrong chapter(s)? Let us know.